CANCER - Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life

www.cancer-nemi.eu

During this RISE project we aim to develop nanoparticle-based encapsulated libraries of different immunotherapeutic biomolecules for treatment after surgery as part of a novel cancer management strategy. The current state-of-art for the management of cancer starts with surgery, after identification of an accessible tumour mass. Surgery remains an effective treatment option for many types of cancer today and it is considered curative treatment for most solid tumours. It forms part of a multidisciplinary approach used in conjunction with radiotherapy or chemotherapy. These approaches, however, have several limitations, including inability of surgical resection to affect distal metastatic disease, toxicity to healthy tissues with chemotherapy and lack of effectiveness of radiation therapy in more aggressive tumours. The observation that cancer can relapse months or years after initial surgery implies that micrometastases still resides within the body in a latent state. Our proposal is to take cancer therapy to beyond state-of-art by implementing techniques which will take us into new directions.

This includes a) new methods to identify immune gene profiles and biomarkers b) transgenic mouse models where the complex interactions that underlie immune function can be visualised as multiplexed events in real time and c) the use of nanoparticle-based libraries of immune modulating reagent combinations. There are three key objectives within this project: i) to use immune gene signatures to monitor disease progression and therapeutic efficacy of immunotherapy combinations on nanoparticle-based platforms, ii) to optimise the platform to encapsulate libraries of immune components for more personalised, accurate and timely delivery of the payload to its intended target and iii) to optimise the overall cancer management process of image-guided surgery followed by postoperative immunotherapy so that we can ultimately provide a lifetime of protection against cancer.

 

Coordinator: PERCUROS BV Netherlands 2333 BZ LEIDEN Netherlands

Start Date: 2018-03-01 /End Date: 2022-02-28

Info at Cordis: https://cordis.europa.eu/project/rcn/212968_en.html

 

Acronimo: 
CANCER
Soggetto finaziatore: 
Unione Europea
Programma di Finanziamento e bando: 
H2020-MSCA-RISE-2017
Numero del progetto/Contratto: 
777682
Responsabile Scientifico: 
Prof.ssa Piera di Martino
ruolo Unicam: 
Partner
Partner: 
Nome: 
ACADEMISCH ZIEKENHUIS LEIDEN
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
TECHNISCHE UNIVERSITEIT DELFT
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
TECOBIOSCIENCES GMBH
Stato: 
Germany
Ruolo: 
Partner
Nome: 
UNIVERSITEIT VAN AMSTERDAM
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
THE UNIVERSITY OF SHEFFIELD
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
UNIVERSITEIT MAASTRICHT
Stato: 
Netherlands
Ruolo: 
Partner
Nome: 
JENACELL GMBH
Stato: 
Germany
Ruolo: 
Parner
Nome: 
MEDRES-MEDICAL RESEARCH GMBH
Stato: 
Germany
Ruolo: 
Partner
Nome: 
AUGEAS ASSOCIAZIONE DI SPORT PROMOZIONE E TURISMO
Stato: 
Italy
Ruolo: 
Partner
Nome: 
PROGREDUM GMBH
Stato: 
Germany
Ruolo: 
Partner
Nome: 
ASSOCIAZIONE CULTURALE CASTELLI ROMANI GREEN TOUR
Stato: 
Italy
Ruolo: 
Partner
Nome: 
BOSCHIVA MELCHIORRI SRL
Stato: 
Italy
Ruolo: 
Partner
Nome: 
HELRIK AND LOUW COMPANY LTD
Stato: 
United Kingdom
Ruolo: 
Partner
Nome: 
UNIWERSYTET JAGIELLONSKI
Stato: 
Poland
Ruolo: 
Partner
Tipo di finaziamento: 
Horizon 2020